Silexion Sets 1-for-24 Reverse Split to Reclaim Nasdaq Bid Compliance

Silexion Therapeutics Corp. will consolidate its ordinary shares through a Silexion 1-for-24 reverse share split, the clinical-stage biotechnology company announced Monday. The move is scheduled to take effect after the market closes on November 10, 2026, with split-adjusted trading beginning on the Nasdaq Capital Market at the open on November 11 under the existing ticker symbol SLXN.

The company said the consolidation is intended to help it regain compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2). Silexion also expects the adjustment to strengthen its market position and support strategic growth initiatives, including equity financings.

What the Reverse Share Split Changes

GlobeNewswire

Under the ratio, every 24 issued and outstanding ordinary shares will automatically combine into one share. The par value will rise proportionately from $0.135 per share to $3.24 per share. No fractional shares will be issued, and direct participants in the DTC system who are entitled to fractional shares will each receive a rounded-up whole share.

The post-split shares have been assigned the new CUSIP number G1281K163 and are set to begin trading on November 11, 2026.

Shareholders holding shares in book-entry form do not need to take any action, as their holdings will be adjusted automatically. Those holding through a broker or nominee also do not need to act; their share counts will be adjusted automatically in their brokerage accounts. Shareholders with questions about their accounts should contact their broker.

Leadership Links Move to Clinical and Financial Goals

Ilan Hadar, chairman and CEO of Silexion, described the reverse split as a deliberate step to preserve the company’s Nasdaq listing and reinforce the capital structure supporting its clinical execution. He said the higher per-share trading price expected after the split should help address the bid price deficiency, reduce volatility, broaden the pool of investors able to engage with the company and improve flexibility to fund continued advancement of SIL204.

Hadar also pointed to progress in the active stage of the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, noting that the first patient was dosed in September.

Pipeline and Company Background

Silexion Therapeutics is an oncology-focused, clinical-stage biotechnology company developing treatments for solid tumor cancers driven by the mutated KRAS oncogene, which it describes as generally the most common oncogenic gene driver in human cancers. The company is advancing its lead second-generation product candidate, SIL204, a small interfering RNA (siRNA), through Phase 2/3 clinical evaluation.

Its first-generation product candidate previously completed a Phase 2a clinical trial that showed a positive trend compared with chemotherapy alone, according to the company. Silexion says it is focused on developing its lead candidate for locally advanced pancreatic cancer.

Forward-Looking Statements and Risks

The announcement included forward-looking statements subject to risks and uncertainties. Among the factors that could cause actual results to differ are the ability to enroll, treat and evaluate patients in accordance with the study protocol, including an initial safety run-in cohort of approximately 18 patients and a randomized expansion cohort of approximately 166 patients.

Other risks include the possibility that preliminary safety, tolerability, response rate or survival data may not be achieved, confirmed or replicated as the trial advances, that early observations may not predict final results, or that SIL204 may not show statistically significant clinical efficacy improvements over chemotherapy alone. The company also cited risks related to site activation at additional medical centers in Israel and Germany, regulatory approvals and compliance complexities, future capital requirements and sources of cash, and the ability to maintain its Nasdaq listing, including remedying deficiencies related to minimum bid price and minimum shareholders’ equity.

Silexion referred to its Annual Report on Form 10-K for the year ended December 31, 2025, filed March 17, 2026, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, and June 30, 2026, filed May 15, 2026, and August 14, 2026, respectively, for additional risks and uncertainties.

Leave a comment

Your email address will not be published. Required fields are marked *